05Dec 2023
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT)

Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT)

Results from the phase 3 COVID-OUT trial unveil a groundbreaking discovery: outpatient treatment with metformin significantly reduces the risk of long COVID by 41%. With data from 1323 participants, this study emphasizes metformin's clinical benefits as a cost-effective, globally available, and safe solution for COVID-19 outpatient treatment. The findings provide a promising avenue for managing post-COVID-19 conditions and contribute valuable insights to global healthcare strategies.

  • #general medicine

Like

Save

Share